Q-linea AB (publ) (STO:QLINEA)

Market Cap	282.34M +74.1%
Revenue (ttm)	12.81M +19.4%
Net Income	-139.73M
EPS	-14.28
Shares Out	18.95M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	8,845
Open	14.85
Previous Close	14.55
Day's Range	14.55 - 14.90
52-Week Range	14.05 - 38.43
Beta	0.50
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 30, 2026

About Q-linea AB

Q-linea AB (publ) engages in the manufacturing and sale of instruments and consumables diagnose and treat infectious diseases in the United Kingdom, the United States, France, the Middle East, Belgium, Italy, and Finland. It offers ASTar, an antimicrobial susceptibility testing (AST) technology used in the treatment of bloodstream infections and sepsis; and ASTar BC G- Kit which contains two disposables, including a sample preparation cartridge and an AST disc, used with the Frozen insert. The company also develops Podler, a portable blood cult...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 2007
• Employees: 70
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: QLINEA

Financial Performance

In 2025, Q-linea AB's revenue was 15.29 million, an increase of 269.29% compared to the previous year's 4.14 million. Losses were -182.49 million, -15.86% less than in 2024.

Data Sources: S&P Global Market Intelligence and QUODD

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by QUODD.

Last checked:

Nov 4, 2026

Data Sources Report a data error